Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (April 2006)
10 slides from Somnomed's investor presentation, Apr 27, 2006
Slide 1: North America Investor Presentation
North America Investor Presentation April 26, 2006
Slide 2: Why are we here
Why are we here Context Our Objective Have completed a new facility in Denton Texas, which was up and running on April 1 2006 Set up coincides the new practice parameters published by the American Academy of Sleep Medicine and endorsed by the Academy of Dental Sleep Medicine that promotes oral appli
Slide 3: The Market: estimated 30 million snorers in the US
The Market: in the US there are an estimated 30million snorers and 18 million who have a likelihood of having or developing sleep apnea OSA and Snoring Market i O84 Syndrome* » CPAP | © & mer : Market % | B4wemen _ oGae : : 20% men 7% werner Habitual _ Shorers* SommoMed MAS PAM het Market 28% women
Slide 4: Currently the default treatment after lifestyle change is CPAP
Currently the default treatment after lifestyle change is CPAP Habitual Searing Snoring and Mild O54 Alle S AHL 5-1 Snoring amd Mederate OSA AHI 15-30 Snoring and Severs OSA AHL > JE CRAP Unlikely [17 Possibly 12) SommoMed MAS Secastonaly EY Note 1: ‘Unlikely [1] in the above table means habitual sn
Slide 5: ResMed is one of the leading CPAP suppliers
ResMed is one of the leading CPAP suppliers Source: Brokers Report, Citigroup eae rien a lee |
Slide 6: US Sleep Therapy Penetration
US Sleep Therapy Penetration US Sleep Therapy market is modestly penetrated Still Plenty of Room for Growth Source: Wachovia Securities One estimate puts US obstructive sleep apnea prevalence as 7% of the US adult population or about 15MM patients Other estimates are as high as 40- 50MM which would
Slide 7: Financial Opportunity: illustrative unit sales economics
Financial Opportunity: this table illustrates the financial economics for unit sales ranging from 10K units to 100K units Unit Sates 10,000 25,000 50,000 75,000 106,000 Selling Price $495 $495 $495 $495 $495 ile Sales $4,950,000 $12,375,000 $24,750,000 $37,125,000 $49,500,000 Gross Profit $2,970,000
Slide 8: SomnoMed the platform is in place
SomnoMed the platform is in place American Academy of Sleep Medicine; now . recommending MAS as a first line treatment . Market size: in USA annual sales of (CPAP) . estimated at $440million Estimates are that over time in excess of . 40% of CPAP users become non-compliant No standard device or trea
Slide 9: Who is SomnoMed
Who is SomnoMed August 2004 December 2004 January 2005 February 2005 July 2005 August 2005 September 2005 October 2005 December 2005 April 2006 Listed on ASX Laboratory completed in Sydney Sydney laboratory producing devices Decision not to build second laboratory in Australia USA FDA Approval recei
Slide 10: Corporate Statistics
Corporate Statistics Number of Shares on Issue Number of Options on Issue Six Month Volume Shares traded Top Ten Shareholders Ownership Six Month Share Price Range Current Share Price (April 24th) Date of IPO Net Assets 31% March 2006 Sales YTD March 315! 2006 See Website: www.SomnoMed.com 114,900,0